VERTEX PHARMACEUTICALS INC / MA (VRTX)
$541.15-$6.40 (-1.17%) Today
Duncan McKechnie - OfficerVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 14,094 | $6.63M |
| Grant or award | 4 | 16,634 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
119 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kristen Ambrose - Officer | Tax withholding / forfeiture | Common Stock | 598 | $483.75 | $289K | |
| Kristen Ambrose - Officer | Open-market sale | Common Stock | 638 | $473.68 | $302K | |
| Kristen Ambrose - Officer | Grant or award | Common Stock | 1,809 | $0.00 | - | |
| Kristen Ambrose - Officer | Open-market sale | Common Stock | 1,557 | $489.46 | $762K | |
| Charles F. Wagner Jr. - Officer | Tax withholding / forfeiture | Common Stock | 4,565 | $487.76 | $2.23M | |
| Ourania Tatsis - Officer | Tax withholding / forfeiture | Common Stock | 3,804 | $487.76 | $1.86M | |
| Ourania Tatsis - Officer | Open-market sale | Common Stock | 1,500 | $499.99 | $750K | |
 Amit Sachdev - Officer | Tax withholding / forfeiture | Common Stock | 3,548 | $487.76 | $1.73M | |
| Duncan McKechnie - Officer | Tax withholding / forfeiture | Common Stock | 2,283 | $487.76 | $1.11M | |
 Reshma Kewalramani - Officer | Tax withholding / forfeiture | Common Stock | 13,041 | $487.76 | $6.36M | |
| Mark E. Bunnage - Officer | Tax withholding / forfeiture | Common Stock | 2,283 | $487.76 | $1.11M | |
| Carmen Bozic - Officer | Tax withholding / forfeiture | Common Stock | 3,804 | $487.76 | $1.86M | |
 Jonathan Biller - Officer | Tax withholding / forfeiture | Common Stock | 2,993 | $487.76 | $1.46M | |
| Jonathan Biller - Officer | Open-market sale | Common Stock | 988 | $499.00 | $493K | |
| Sangeeta N. Bhatia - Director | Open-market sale | Common Stock | 266 | $500.00 | $133K | |
| Edward Morrow Atkinson III - Officer | Tax withholding / forfeiture | Common Stock | 1,903 | $487.76 | $928K | |
| Kristen Ambrose - Officer | Tax withholding / forfeiture | Common Stock | 1,393 | $487.76 | $679K | |
| Charles F. Wagner Jr. - Officer | Tax withholding / forfeiture | Common Stock | 3,045 | $468.41 | $1.43M | |
| Ourania Tatsis - Officer | Tax withholding / forfeiture | Common Stock | 2,140 | $468.41 | $1.00M | |
| Ourania Tatsis - Officer | Open-market sale | Common Stock | 466 | $460.43 | $215K | |
| Amit Sachdev - Officer | Tax withholding / forfeiture | Common Stock | 2,057 | $468.41 | $964K | |
| Duncan McKechnie - Officer | Tax withholding / forfeiture | Common Stock | 1,127 | $468.41 | $528K | |
| Reshma Kewalramani - Officer | Tax withholding / forfeiture | Common Stock | 8,297 | $468.41 | $3.89M | |
| Mark E. Bunnage - Officer | Tax withholding / forfeiture | Common Stock | 1,127 | $468.41 | $528K | |
| Mark E. Bunnage - Officer | Open-market sale | Common Stock | 2,021 | $460.43 | $931K | |
| Carmen Bozic - Officer | Tax withholding / forfeiture | Common Stock | 2,145 | $468.41 | $1.00M | |
| Jonathan Biller - Officer | Tax withholding / forfeiture | Common Stock | 1,630 | $468.41 | $764K | |
| Jonathan Biller - Officer | Open-market sale | Common Stock | 1,925 | $460.43 | $886K | |
| Edward Morrow Atkinson III - Officer | Tax withholding / forfeiture | Common Stock | 872 | $468.41 | $408K | |
| Edward Morrow Atkinson III - Officer | Open-market sale | Common Stock | 1,751 | $460.43 | $806K | |
| Kristen Ambrose - Officer | Tax withholding / forfeiture | Common Stock | 592 | $468.41 | $277K | |
| Kristen Ambrose - Officer | Open-market sale | Common Stock | 1,376 | $460.43 | $634K | |
| Charles F. Wagner Jr. - Officer | Grant or award | Common Stock | 9,440 | $0.00 | - | |
| Charles F. Wagner Jr. - Officer | Grant or award | Common Stock | 4,160 | $0.00 | - | |
| Ourania Tatsis - Officer | Grant or award | Common Stock | 7,866 | $0.00 | - | |
| Ourania Tatsis - Officer | Grant or award | Common Stock | 3,883 | $0.00 | - | |
| Amit Sachdev - Officer | Grant or award | Common Stock | 7,866 | $0.00 | - | |
| Amit Sachdev - Officer | Grant or award | Common Stock | 3,883 | $0.00 | - | |
| Duncan McKechnie - Officer | Grant or award | Common Stock | 4,720 | $0.00 | - | |
| Duncan McKechnie - Officer | Grant or award | Common Stock | 2,080 | $0.00 | - | |
| Jeffrey M. Leiden - Officer | Grant or award | Common Stock | 9,012 | $0.00 | - | |
| Reshma Kewalramani - Officer | Grant or award | Common Stock | 26,972 | $0.00 | - | |
| Reshma Kewalramani - Officer | Grant or award | Common Stock | 11,885 | $0.00 | - | |
| Carmen Bozic - Officer | Grant or award | Common Stock | 7,866 | $0.00 | - | |
| Carmen Bozic - Officer | Grant or award | Common Stock | 3,467 | $0.00 | - | |
| Jonathan Biller - Officer | Grant or award | Common Stock | 6,294 | $0.00 | - | |
| Jonathan Biller - Officer | Grant or award | Common Stock | 2,774 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 119 VRTX filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Bruce I. Sachs | Director | 1,210 | $663K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
VERTEX PHARMACEUTICALS INC / MA (VRTX) had 13 insider filings in the last 90 days, with the most recent on 2026-07-23. The full record for VRTX runs to 119 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of VRTX were filed in the last 90 days. 4 purchases are on record for this company.
9 insider sales of VRTX were filed in the last 90 days, totaling $6.63M.
This page tracks VRTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VRTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
